Predictive Oncology Shares Gain 33% After Ovarian Cancer AI Study

Dow Jones05-29

By Matt Walker

Predictive Oncology Inc. shares rose 33% after the company said it will present positive results from a study using its artificial intelligence to more accurately predict survival outcomes among ovarian cancer patients.

Shares were 33% higher at $2.10 at 3:29 p.m. EDT on Tuesday.

The purpose of the study was to determine if Predictive Oncology "could leverage its artificial intelligence and other capabilities to develop machine learning models that could more accurately predict both short-term (two-year) and long-term (five-year) survival outcomes among ovarian cancer patients," the company said.

Predictive Oncology collaborated with UPMC Magee-Womens Hospital on the study.

"The ability to employ ML to better predict patient prognoses may help with clinical management and monitoring and could serve as a decision support tool to better tailor treatment plans to individual patients," said Robert Edwards, co-director, Gynecologic Oncology Research, Magee-Womens Hospital of UPMC. "The results of this study strongly support continued development of such ML models and subsequent incorporation into daily clinical practice."

Write to Matt Walker at matthew.walker@dowjones.com

(END) Dow Jones Newswires

May 28, 2024 15:46 ET (19:46 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2439804587?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-05-29 03:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2439804587","market":"other","top_or_hot":-1,"title":"Predictive Oncology Shares Gain 33% After Ovarian Cancer AI Study","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Matt Walker \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/POAI\">Predictive Oncology</a> Inc. shares rose 33% after the company said it will present positive results from a study using its artificial intelligence to more accurately predict survival outcomes among ovarian cancer patients. \n</p>\n<p>\n  Shares were 33% higher at $2.10 at 3:29 p.m. EDT on Tuesday. \n</p>\n<p>\n  The purpose of the study was to determine if Predictive Oncology \"could leverage its artificial intelligence and other capabilities to develop machine learning models that could more accurately predict both short-term (two-year) and long-term (five-year) survival outcomes among ovarian cancer patients,\" the company said. \n</p>\n<p>\n  Predictive Oncology collaborated with UPMC Magee-Womens Hospital on the study. \n</p>\n<p>\n  \"The ability to employ ML to better predict patient prognoses may help with clinical management and monitoring and could serve as a decision support tool to better tailor treatment plans to individual patients,\" said Robert Edwards, co-director, Gynecologic Oncology Research, Magee-Womens Hospital of UPMC. \"The results of this study strongly support continued development of such ML models and subsequent incorporation into daily clinical practice.\" \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Matt Walker at matthew.walker@dowjones.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 28, 2024 15:46 ET (19:46 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Predictive Oncology Shares Gain 33% After Ovarian Cancer AI Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPredictive Oncology Shares Gain 33% After Ovarian Cancer AI Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-29 03:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Matt Walker \n\n\n \n\n\nPredictive Oncology Inc. shares rose 33% after the company said it will present positive results from a study using its artificial intelligence to more accurately predict ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2439804587","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2439804587","pubTimestamp":1716925560,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Predictive Oncology Inc. shares rose 33% after the company said it will present positive results from a study using its artificial intelligence to more accurately predict survival outcomes among ovarian cancer patients.Shares were 33% higher at $2.10 at 3:29 p.m. EDT on Tuesday.The purpose of the study was to determine if Predictive Oncology \"could leverage its artificial intelligence and other capabilities to develop machine learning models that could more accurately predict both short-term  and long-term  survival outcomes among ovarian cancer patients,\" the company said.Predictive Oncology collaborated with UPMC Magee-Womens Hospital on the study.\"The ability to employ ML to better predict patient prognoses may help with clinical management and monitoring and could serve as a decision support tool to better tailor treatment plans to individual patients,\" said Robert Edwards, co-director, Gynecologic Oncology Research, Magee-Womens Hospital of UPMC. \"The results of this study strongl","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","POAI":"Predictive Oncology","BK4198":"医疗保健用品"},"translate_title":"卵巢癌人工智能研究后，预测肿瘤学份额增长33%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"POAI":1},"content_text":"By Matt Walker \n\n\n \n\n\nPredictive Oncology Inc. shares rose 33% after the company said it will present positive results from a study using its artificial intelligence to more accurately predict survival outcomes among ovarian cancer patients. \n\n\n  Shares were 33% higher at $2.10 at 3:29 p.m. EDT on Tuesday. \n\n\n  The purpose of the study was to determine if Predictive Oncology \"could leverage its artificial intelligence and other capabilities to develop machine learning models that could more accurately predict both short-term (two-year) and long-term (five-year) survival outcomes among ovarian cancer patients,\" the company said. \n\n\n  Predictive Oncology collaborated with UPMC Magee-Womens Hospital on the study. \n\n\n  \"The ability to employ ML to better predict patient prognoses may help with clinical management and monitoring and could serve as a decision support tool to better tailor treatment plans to individual patients,\" said Robert Edwards, co-director, Gynecologic Oncology Research, Magee-Womens Hospital of UPMC. \"The results of this study strongly support continued development of such ML models and subsequent incorporation into daily clinical practice.\" \n\n\n \n\n\n  Write to Matt Walker at matthew.walker@dowjones.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 28, 2024 15:46 ET (19:46 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2439804587"}